dibenz(a,j)anthracene-3,4-diol-1,2-epoxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 180017 |
| CHEMBL ID | 24244 |
| MeSH ID | M0161838 |
| Synonym |
|---|
| db(aj)a-de |
| CHEMBL24244 |
| trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydrodibenz(a,j)anthracene |
| 121209-33-4 |
| naphtho(1',2':6,7)phenanthro(3,4-b)oxirene-2,3-diol, 1a,2,3,13c-tetrahydro-, (1aalpha,2beta,3alpha,13calpha)- |
| 119181-08-7 |
| dibenz(a,j)anthracene-3,4-diol-1,2-epoxide |
| db(a,j)a-diol-epoxide |
| naphtho(1',2':6,7)phenanthro(3,4-b)oxirene-2,3-diol, 1a,2,3,13c-tetrahydro-, (1aalpha,2beta,3alpha,13calpha)-(+-)- |
| dibenz(a,j)anthracene trans-3,4-diol-anti-1,2-epoxide |
| 1a,2,3,13c-tetrahydrobenzo[10,11]tetrapheno[1,2-b]oxirene-2,3-diol |
| 114326-34-0 |
| DTXSID20921324 |
| (18s,19r,20r,22s)-21-oxahexacyclo[12.9.0.03,12.04,9.017,23.020,22]tricosa-1(14),2,4,6,8,10,12,15,17(23)-nonaene-18,19-diol |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID127221 | Compound was tested at a dose of 400 nmol for the skin tumor initiating activity expressed as papillomas per mouse | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis of the tumorigenic 3,4-dihydrodiol metabolites of dibenz[a,j]anthracene and 7,14-dimethyldibenz[a,j]anthracene. |
| AID127222 | Compound was tested at a dose of 400 nmol for the skin tumor initiating activity expressed as percent of mice with papillomas | 1988 | Journal of medicinal chemistry, Jul, Volume: 31, Issue:7 | Synthesis of the tumorigenic 3,4-dihydrodiol metabolites of dibenz[a,j]anthracene and 7,14-dimethyldibenz[a,j]anthracene. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||